- Full draft protocol Q1 2024 (after formative research)
- 3 dose regimen
- Continue to include – potential to inform future MDA design and improved effectiveness/cost effectiveness of MDAs, improved clinical management
- Alejandro to share potential protocol/design for salivary testing of [[Albendazol]] (e.g. 48 hours after dose 3) to complement
- Alejandro to share potential protocol/design for salivary testing of [[Albendazol]] (e.g. 48 hours after dose 3) to complement reported coverage data.
- Economics – Contributes also to WP3 (KEMRI)
- GHS RDD to consider options for inclusion of key costing data points